Investor Presentation Q1 2018

Investor Presentation First three months of 2018 Slide 63 GLP-1 patients primarily switch from OADs and untapped potential is large with many OAD patients not in control GLP-1 source of business (new-to-brand prescription market share) Insulin and Treatment Share of patients on OADs achieving HbA1c below 7% in major European countries GLP-1 naive 5% 5% Insulin 29% 51% GLP-1 9% OAD HbA1c >7% 43% 57% Note: Data based on data from France, Germany, UK and USA only OAD: Oral anti-diabetic (includes but is not limited to DPP-IV, SGLT-2, metformin and sulfonylurea) Source: IQVIA Disease Analyser (France, Germany and UK) and IQVIA (formerly IMS) LRX (USA), Sep 2017 Note: Data based on data from France, Germany and UK only Source: IQVIA Disease Analyser (France, Germany and UK), Sep 2017 HbA1c <7% novo nordisk

View entire presentation